Pre-PD

Smartphone Speech Testing for Symptom Assessment in Rapid Eye Movement Sleep Behavior Disorder and Parkinson’s Disease

Biomarkers, iRBD, Pre-PD, Symptoms / Diagnosis /

We analyzed 4242 smartphone voice recordings collected in clinic and at home from 92 Controls, 112 RBD and 335 PD participants. We used acoustic signal analysis and machine learning, employing 337 features that quantify different properties of speech impairment. Using a leave-one-subject-out cross-validation scheme, we were able to distinguish RBD from controls (sensitivity 60.7%, specificity […]

Smartphone Speech Testing for Symptom Assessment in Rapid Eye Movement Sleep Behavior Disorder and Parkinson’s Disease Read More »

Blood Pressure Patterns in Patients with Parkinson’s Disease: A Systematic Review

Biomarkers, Cardiovascular, Pre-PD, Symptoms / Diagnosis /

Patients with Parkinson’s disease have significantly altered blood pressure patterns that carry a negative prognosis. Ambulatory blood pressure monitoring should be validated as a biomarker of PD-associated cardiovascular dysautonomia and a tool for assistingtherapeutic interventions. CLICK TO REVIEW

Blood Pressure Patterns in Patients with Parkinson’s Disease: A Systematic Review Read More »

Development of early diagnosis of Parkinson’s disease and comprehensive economic analysis of the effect of its implementation

Biomarkers, Pre-PD, Symptoms / Diagnosis /

This approach can also be used to verify blood markers identified in patients at the clinical stage of PD. It is also evident that the complex socioeconomic factors influencing the incidence of PD is different in developed versus developing countries. The societal and medical costs of Parkinson’s are huge and efforts to improve early preclinical

Development of early diagnosis of Parkinson’s disease and comprehensive economic analysis of the effect of its implementation Read More »

Parkinson’s Disease: Alterations in Iron and Redox Biology as a Key to Unlock Therapeutic Strategies

Detox, Iron, Pre-PD /

 This dysfunction could then drive alterations in iron trafficking that attempt to rescue energy deficits such as the increased iron uptake to provide iron for key electron transport proteins. Considering the increased iron-loading in PD brains, therapies utilizing limited iron chelation have shown success. Greater therapeutic advancements should be possible once the exact molecular pathways

Parkinson’s Disease: Alterations in Iron and Redox Biology as a Key to Unlock Therapeutic Strategies Read More »

Spectrum of Non-Motor Symptoms in Parkinson’s Disease

A-Synuclein, Biomarkers, Gut Dysbiosis, iRBD, Olfactory, Pre-PD /

Parkinson’s disease is predominantly classified as a movement disorder. Beyond the textbook definition of rigidity, tremors, and bradykinesia, Parkinson’s disease encompasses an entire entity of non-motor symptom complexes that can precede the motor features by many years. Despite their significant clinical importance, the awareness of non-motor symptoms is quite negligible. Sleep disorders, gastrointestinal dysfunction, olfactory

Spectrum of Non-Motor Symptoms in Parkinson’s Disease Read More »

Clinical characteristics of newly diagnosed Parkinson’s disease patients included in the longitudinal BIO-PD study

Biomarkers, Pre-PD, Symptoms / Diagnosis /

The frequencies of symptoms and abnormal findings in PD patients were as follows: hyposmia 82.4%, substantia nigra hyperechogenicity 75.4%, history of anxiety or depression disorder 29.5%, constipation 22.1%, and REM (rapid eye movement) sleep behavior disorder 22%. Conclusion: Baseline characteristics of patients enrolled in the BIO-PD study are comparable to other de novo PD cohorts,

Clinical characteristics of newly diagnosed Parkinson’s disease patients included in the longitudinal BIO-PD study Read More »

Effects of Resistant Starch on Symptoms, Fecal Markers and Gut Microbiota in Parkinson’s Disease – The RESISTA-PD Trial

Butyrate, Pre-PD, Probiotics, Prebiotics and Symbiotics, Short Chain Fatty Acids, Therapies /

Clinically, we observed a reduction in non-motor symptoms load in PD + RS. The reference-based analysis of metagenomes highlighted stable alpha-diversity and beta-diversity across the three groups, including bacteria producing SCFAs. Reference-free analysis suggested punctual, yet pronounced differences in the metagenomic signature in PD + RS. RESISTA-PD highlights that a prebiotic treatment with RS is

Effects of Resistant Starch on Symptoms, Fecal Markers and Gut Microbiota in Parkinson’s Disease – The RESISTA-PD Trial Read More »

Smell tests to distinguish Parkinson’s disease from other neurological disorders: a systematic review and meta-analysis

Biomarkers, Olfactory, Pre-PD, Symptoms / Diagnosis /

Olfactory impairment has been considered for differential diagnosis in Parkinson’s Disease (PD) patients. The authors aimed to identify the tests used to assess the olfactory function in PD patients and examine these tests’ ability to distinguish them from other neurological disorders. CLICK TO REVIEW

Smell tests to distinguish Parkinson’s disease from other neurological disorders: a systematic review and meta-analysis Read More »